QuantumHealth
AI-powered early cancer detection from a single blood draw
QuantumHealth's liquid biopsy platform detects 12 types of cancer at Stage I–II with 94% sensitivity using a standard blood draw. We've completed a 400-patient clinical study at three Canadian hospitals, received Health Canada IVD exemption, and have LOIs from two provincial health authorities worth $3.2M ARR.
Most cancers are detected at Stage III–IV when treatment is expensive and outcomes are poor. Existing screening (colonoscopy, mammogram) covers only 4 cancer types, requires invasive procedures, and has low patient compliance. There is no affordable, multi-cancer early detection test available in Canada.
A single blood draw processed through our lab and ML pipeline returns a risk report for 12 cancer types within 5 business days. Priced at $180/test for hospitals — less than a standard MRI — and designed to integrate with existing EMR systems.
"What would you still be building if you knew it would take 10 years?"
The science is unambiguous: early detection saves lives. Getting this into provincial health systems may take a decade of regulatory work. I'd do every day of it.
— Dr. Aisha Okonkwo, CEO
QuantumHealth's proprietary assay uses machine learning on cell-free DNA methylation patterns to identify tumour signals across 12 cancer types with a single 10mL blood draw. At Stage I detection, 5-year survival rates exceed 90% vs 15–30% at Stage IV. Our 400-patient prospective study at McGill, Toronto General, and BC Cancer demonstrated 94% sensitivity, 97% specificity.
400-patient clinical study complete at three major Canadian hospitals. 94% sensitivity / 97% specificity validated by independent biostatisticians. Health Canada IVD Class II exemption granted. 2 LOIs from provincial health authorities representing $3.2M ARR.
Criteria used by early-stage investors (YC, Sequoia seed, BDC Capital) to evaluate pre-seed companies.
| Criterion | Status | Value | Note |
|---|---|---|---|
| Clinical evidence | ✓ | 400 patients | Peer-reviewed, published |
| Regulatory exemption | ✓ | Granted | Health Canada IVD Class II |
| Lead investor | ✓ | BDC Capital | $250k committed |
| Revenue | ✗ | $0 | Pre-revenue |
| Runway | ~ | 10 months | High burn, time-sensitive raise |
| Regulatory path | ~ | 18-24 months | Class III approval pending |
Tap any milestone to see details.
BDC's health tech fund is leading this round. Their venture partner Dr. Rachel Sato joins our advisory board.
Our 400-patient study results are now peer-reviewed and published. Independent validation of 94% sensitivity.
"Explain your startup like I'm 12"
When you get a cut, your blood carries tiny bits of information about what's happening inside your body. We taught a computer to read those tiny bits and spot cancer really early — before you feel sick — just from a regular blood test.
— Dr. James Park, CTO